Get the Stockscreener App
3.74
3.86%
-0.15
After Hours:
3.75
0.010
+0.27%
Ardelyx Inc stock is traded at $3.74, with a volume of 5.21M.
It is down -3.86% in the last 24 hours and down -25.65% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.89
Open:
$3.88
24h Volume:
5.21M
Relative Volume:
1.29
Market Cap:
$965.62M
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-15.70
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
-7.88%
1M Performance:
-25.65%
6M Performance:
-42.99%
1Y Performance:
-38.79%
1-Day Range:
$3.725
$3.89
1-Week Range:
$3.725
$4.09
52-Week Range:
$3.725
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.74 | 1.01B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx (NASDAQ: ARDX) holder plans tax sale of vesting shares - Stock Titan
Ardelyx (NASDAQ: ARDX) exec plans 10,500-share RSU tax sale - Stock Titan
Ardelyx (NASDAQ: ARDX) insider plans $179K stock sale - Stock Titan
Ardelyx (NASDAQ: ARDX) plans RSU tax-cover sale of 10,500 shares - Stock Titan
Ardelyx (ARDX) exec to sell $18.9K in shares for RSU taxes - Stock Titan
Ardelyx (NASDAQ: ARDX) shareholder John Bishop plans 25,500-share sale - Stock Titan
Ardelyx (NASDAQ: ARDX) officer plans stock sales and tax-cover trades - Stock Titan
Ardelyx (ARDX) officer to sell 11,900 shares for RSU taxes - Stock Titan
334,115 Shares in Ardelyx, Inc. $ARDX Acquired by Clay Northam Wealth Management LLC - MarketBeat
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Ardelyx (ARDX) Securities Investigation NoticeLevi & Korsinsky - Morningstar
Ardelyx (NASDAQ:ARDX) Sets New 52-Week LowHere's Why - MarketBeat
Ardelyx (ARDX) Earnings Update: EPS Falls Short of Its Estimate under the Current Snapshot; Investor Response: Shares Fall 2.61% at the CloseRevenue Inflection Point - vinanet.vn
Ardelyx (ARDX) Following Strong Results And Guidance Still Looks Undervalued - simplywall.st
ARDX Reiterates by Wedbush -- Price Target Maintained at $9.00 - GuruFocus
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Ardelyx Chief Commercial Officer Announces Upcoming Resignation - The Globe and Mail
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript - AOL.com
Ardelyx, Inc. (ARDX) Latest Stock News & Headlines - Yahoo Finance
Wedbush Reiterates Outperform Rating for Ardelyx (NASDAQ:ARDX) - MarketBeat
Ardelyx Leads The Charge With These 3 Compelling Penny Stocks - Sahm
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx Announces Resignation of Chief Commercial Officer Eric Foster Effective August 28, 2026 - Kalkine Media
Ardelyx, Inc. Announces Resignation of Eric Foster from Chief Commercial Officer, Effective August 28, 2026 - marketscreener.com
ARDX Maintained by Piper Sandler -- Price Target Lowered to $15.00 - GuruFocus
Piper Sandler Lowers Ardelyx (NASDAQ:ARDX) Price Target to $15.00 - MarketBeat
ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX) - Business Wire
AIGH Capital Management LLC Buys Shares of 3,200,000 Ardelyx, Inc. $ARDX - MarketBeat
Rubric Capital discloses 6.56% Ardelyx (ARDX) stake totaling 16.2M shares - Stock Titan
ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx - TradingView
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) - Morningstar
Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance - simplywall.st
Ardelyx (NASDAQ:ARDX) Hits New 12-Month LowShould You Sell? - MarketBeat
Ardelyx Q2 revenue up 31% but guidance cut due to payer issues, hold rating maintained - Pluang
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story (NASDAQ:ARDX) - Seeking Alpha
Ardelyx, Inc. (ARDX) stock price, news, quote and history - Yahoo Finance Singapore
Is Ardelyx (ARDX) Undervalued Following Q2 Results And Updated Product Guidance? - simplywall.st
Ardelyx (ARDX): Millennium entities and Israel Englander report 5.7% stake in 13G/A - Stock Titan
Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History - Yahoo Finance
HC Wainwright Estimates Ardelyx's Q3 Earnings (NASDAQ:ARDX) - MarketBeat
Ardelyx, Inc. (ARDX) interactive stock chart - Yahoo Finance Singapore
Ardelyx (ARDX) Is Down 19.7% After Raising IBSRELA Revenue Guidance And Narrowing Losses - Yahoo Finance
3 High Growth Stocks With Healthy Balance Sheets Retail Investors May Be Missing - simplywall.st
ARDX Maintained by Citigroup -- Price Target Lowered to $11.00 - GuruFocus
Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $11.00 - MarketBeat
3 Financially Strong Penny Stocks Worth A Closer Look - simplywall.st
3 Financially Fit Penny Stocks Retail Investors May Be Missing - Sahm
FY2027 EPS Estimates for Ardelyx Lowered by HC Wainwright - MarketBeat
Ardelyx Stock Leads These Financially Fit Penny Stocks Worth A Closer Look - simplywall.st
Ardelyx Lawsuit 2026: Payouts, Eligibility, Updates - LawFold.com
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):